RXi Pharmaceuticals Announces Participation in Leading European Healthcare Forums and Conferences

MARLBOROUGH, Mass., Nov. 7, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, announced today that its leadership team will be participating in several leading European healthcare forums and conferences. 

November 13, 2017 – World HealthEx Forum
On November 13, 2017, Dr. Karen Bulock, Vice President of Research at RXi Pharmaceuticals, will participate in the Immuno-Oncology HealthEx World Forum, one of eight dynamic sessions taking place at World HealthEx Forum.  Industry leaders will gather to discuss and address key challenges for businesses fighting the most devastating human diseases of our time. 

This forum provides a platform for executives from pharma, health technology, finance, and government dedicated to finding solutions to the health industry's most pressing challenges through debate, dialogue, and collaboration. This conference will take place November 13, 2017, at 200 Aldersgate, London, UK.

November 14, 2017 – Biotech and Money Inv€$tival Showcase
Dr. Bulock will present during the 2017 Inv€$tival Showcase on November 14, 2017, at 1:45 pm GMT where she will discuss the Company's proprietary self-delivering RNAi (sd-rxRNA®) platform and demonstrate its broad applicability for cell-based immunotherapies to treat cancer. 

In an exclusive partnership with Jefferies LLC, the Inv€$tival Showcase spans 4-tracks and will feature the most exciting companies across seven key sub-sectors within life sciences. The global list of presenting companies will span corporates involved in the World HealthEx Forum on November 13, as well as the most exciting and innovative new companies looking to raise capital or profile with investors, brought together through both Biotech and Money and Jefferies' investor networks. This conference will take place November 14, 2017, at Waldorf Hilton Hotel London, UK.

November 13-14, 2017 – CEO Forum in Europe
Dr. Geert Cauwenbergh, President and CEO at RXi Pharmaceuticals, will present during a panel on November 14, 2017 to discuss "Raising Capital for your Business" at the CEO Forum in Europe sponsored by YJP.  

This Forum provides for learning and networking opportunities with top-level business executives from both sides of the Atlantic Ocean. The intimate format, organized in part with Bayer, allows for deeper and more meaningful interactions with like-minded executives to explore important topics related to leadership and innovation.  This conference will take place November 13-14, 2017 at Bayer Pharmaceuticals, Berlin, Germany.

November 15-16, 2017 – Jefferies Healthcare Conference
Dr. Cauwenbergh will be participating in the largest 2-day European healthcare conference where he will focus on business development and partnering opportunities. 

Now in its eighth year, the Jefferies Conference is the largest healthcare-dedicated conference in Europe. This year, we hosted 350 participating companies, 1,400 attendees and 3,400 investor and business-to-business meetings. The event featured leading public and private companies from the pharmaceuticals, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors from the United States, Europe, Africa, Middle East, Latin America, Russia, India, Israel, China, and Japan.  The conference will take place November 15-16 in London, UK.

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs.  Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which can be used to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition.  RXi developed a robust RNAi therapeutic platform, including self-delivering RNA (sd-rxRNA®) compounds, that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. Our current programs include dermatology, ophthalmology, and cell-based immunotherapy.  RXi's extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas, and we actively pursue research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies.  For additional information, visit the Company's website, www.rxipharma.com.  

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors."  Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646

Logo- http://mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg

SOURCE RXi Pharmaceuticals Corporation

Related Links

http://www.rxipharma.com